Cyber warning letters
This article was originally published in The Tan Sheet
Executive Summary
FDA has issued several "cyber" letters to Internet dietary supplement marketers for promoting products with improper claims. Cosmeceutical Technologies received a letter from the agency stating that its HoodiThin weight-loss supplement carried inappropriate drug claims on the firm's promotional website. Physician Formulas also made drug claims for its Serrapeptase anti-inflammatory, 5-HTP anti-depressant and Prostate Power Rx supplements, according to a separate FDA letter. Additionally, FDA sent a follow-up letter to Torica Productions concerning statements made for its product The Greatest Vitamin in the World that the agency cited in a letter sent last July. The agency particularly objected to claims and testimonials touting the product's benefits for conditions such as diabetes, stroke, heart disease, insomnia, cancer and arthritis, which would require the product to be regulated as a drug...
You may also be interested in...
Lawyers Question FDA’s Broad Brush Approach In Cancer Claims Crackdown
Dietary supplement trade groups say FDA's recent crackdown on products with unsubstantiated cancer claims helps firms that use appropriate marketing, but food and drug lawyers say the agency may have applied too much of a broad brush approach
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.